Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2006 Results on July 25, 2006.BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN SGEN Signal/System Generator ) announced today that it will report its second quarter 2006 financial results on Tuesday, July 25, 2006, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, July 25, 2006, 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time --Telephone 800-240-7305 (domestic) or 303-262-2139 (international) --Webcast available at www.seattlegenetics.com in the News and Investor Information section REPLAY access --Telephone replay will be available beginning at 4:00 p.m. Pacific Time on July 25, 2006 through 4:00 p.m. Pacific Time on July 27, 2006 by calling 800-405-2236 (domestic) or 303-590-3000 (international); passcode 11065923 --Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the News and Investor Information section About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development of monoclonal monoclonal /mono·clo·nal/ (-klon´al) 1. derived from a single cell. 2. pertaining to a single clone. mon·o·clo·nal n. antibody-based therapies for the treatment of cancer and immunologic immunologic, immunological emanating from or pertaining to immunology. immunologic competence see immunocompetence. immunologic domains diseases. The company is conducting multiple clinical trials of its three lead product candidates, SGN-30, SGN-40 and SGN-33, and preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. development of several late-stage programs, including SGN-35 and SGN-70. In addition, Seattle Genetics has developed proprietary antibody-drug conjugate conjugate /con·ju·gate/ (kon´jdbobr-gat) 1. paired, or equally coupled; working in unison. 2. a conjugate diameter of the pelvic inlet; used alone usually to denote the true conjugate diameter; see (ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. ) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). . The company currently has license agreements for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen and MedImmune. More information about Seattle Genetics' pipeline and technologies can be found at www.seattlegenetics.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion